Abstract. The present study focused on the elucidation of the putative anticancer potential of quercetin. The anticancer activity of quercetin at 10, 20, 40, 80 and 120 µM was assessed in vitro by MTT assay in 9 tumor cell lines (colon carcinoma CT-26 cells, prostate adenocarcinoma LNCaP cells, human prostate PC3 cells, pheocromocytoma PC12 cells, estrogen receptor-positive breast cancer MCF-7 cells, acute lymphoblastic leukemia MOLT-4 T-cells, human myeloma U266B1 cells, human lymphoid Raji cells and ovarian cancer CHO cells). Quercetin was found to induce the apoptosis of all the tested cancer cell lines at the utilized concentrations. Moreover, quercetin significantly induced the apoptosis of the CT-26, LNCaP, MOLT-4 and Raji cell lines, as compared to control group (P<0.001), as demonstrated by Annexin V/PI staining. In in vivo experiments, mice bearing MCF-7 and CT‑26 tumors exhibited a significant reduction in tumor volume in the quercetin-treated group as compared to the control group (P<0.001). Taken together, quercetin, a naturally occurring compound, exhibits anticancer properties both in vivo and in vitro.

Introduction

The development or identification of compounds capable of killing transformed or cancer cells, without being toxic to their normal counterparts, is of utmost importance, and has gained the increasing interest of scientists worldwide. Since antiquity, plants have been considered rich sources of chemicals, with immense therapeutic potential. During recent years, some of these plant-derived compounds or phytochemicals have been shown to be highly competent anticancer agents, in addition to being effective against many other diseases (1-4).

Cancer, following cardiovascular diseases, is the main cause of mortality and morbidity in Europe. The key characteristics of this aggressive disease are uncontrolled growth and the spread of transformed cells (5). Each year, millions of individuals are diagnosed with cancer, whereas approximately 3.5 million cancer-related deaths are annually recorded worldwide (6,7). Specifically, only in Europe, approximately 3.45  million new cases of cancer were reported in 2012, excluding non-melanoma skin cancer, whereas approximately 1.75 million deaths occurred (8).

Throughout history, plant extracts and their purified active components have been the backbone of cancer chemotherapeutics (9). It is estimated that over 70% of anticancer compounds are either natural products, or natural product-derived substances (10).

Natural polyphenols are a large and abundant group of phytochemicals found in herbal beverages and food (11-13). The plethora of these compounds is highlighted by the fact that up to date, over 8,000 polyphenols have been identified.
Structurally, polyphenols consist of aromatic rings which are functionalized with one or more hydroxyl groups (12). Flavonoids and phenolics in particular, represent an important component of a normal human diet (14,15). The average daily flavonoid intake varies from approximately 1-2 g per day (16), depending on the type and the amount of fruit, vegetables or beverages consumed. The existence of a negative correlation between a diet rich in polyphenols and various diseases, such as cancer, cardiovascular and degenerative diseases has been well established (4,17). The total phenolic content (TPC) and the total flavonoid content (TFC) seem to correlate positively with in vivo and in vitro anticancer and antioxidant properties (18). Indeed, The American Institute of Cancer Research has reported that a high intake of fruit and vegetables correlates with a low risk of tumor occurrence (19). In addition, The National Academy of Sciences of the United States (1982) has also laid stress on the importance of fruits and vegetables in cancer prevention by including respective guidelines in its report on diet and cancer (20-22). The polyphenolic compounds have been reported to have many pharmacological activities, such as antioxidant, anti-inflammatory, anticarcinogenic, antiviral, or antiallergic effects (3,4,23-25).

Among anticancer and cancer preventing drugs, flavonoids are the most studied ones. These compounds can interfere with specific stages of the carcinogenic process, inhibit cell proliferation and induce apoptosis in several types of cancer cells (26-30). Flavonoids demonstrate a notable antioxidant activity, not only by inhibiting ROS generation, but also by affecting the activity of sundry detoxifying enzymes, such as cyclooxygenases, lipoygenases and inducible nitric oxide synthase (3,31-33). This antioxidant capacity of flavonoids could possibly account for their anticancer potenicy. Flavonoids have also been found to influence epigenetic alterations by chromatin remodeling (34,35).

Quercetin (3,3',4',5,7-pentahydroxyflavone) belongs to polyphenolic flavonoids which are abundantly found in apples, red grapes, onions, raspberries, honey, cherries, citrus fruits and green leafy vegetables, and exerts various biological effects, including antioxidant, anticancer, antiviral, apoptosis-inducing, protein kinase C-inhibitory, cell cycle modulatory and angiogenesis inhibitory effects. Indeed, quercetin is a unique compound due to its potential to combat cancer-related diseases in a multi-targeted manner (36-38). A number of studies have investigated the anticancer activity of quercetin (39-41). In particular, it has been reported that quercetin at various concentrations, suppresses tumor growth of various cancer cell lines, including breast, colorectal, stomach, head and neck, lung, ovarian, melanoma and leukemia (42-50). In addition, quercetin has been shown to inhibit the release of P-glycoprotein in the MCF-7 cell line and to enhance in vitro anticancer activity of adriamycin in breast cancer cell line (44).

Furthermore, it has been suggested that the chronic administration and daily intake of quercetin may be useful for prevention of some cancer types (51). However, cancer treatment in many cases is not effective, with disease recurrence and/or spreading leading to poor outcomes (52). Thus, development of novel therapeutic strategies remains an important goal in the on-going battle against cancer.

The aim of this study was to investigate the anticancer effects of quercetin in vitro and in vivo. The in vitro experiments were performed using a cohort of 9 representative cell lines. We examined the effects of quercetin on cancer cell proliferation (using MTT assay) and apoptosis [utilizing flow cytometer Annexin V/propidium iodide (PI) and TUNEL assay]. In mice bearing MCF-7 and CT-26 xenographs, we also performed an in vivo evaluation of the effects of quercetin.

Materials and methods

Cell culture. We used the following cancer cell lines: CT-26 which is a mouse colon carcinoma cell line that is widely used for drug development (53); PC-12 cell line which is derived from pheochromocytoma and has been widely used as a model of neuronal differentiation (54); LNCaP (androgen-sensitive cancer line) and PC-3 (androgen-insensitive cancer line) utilized as prostate cancer models; MOLT-4 [the T-cell line that causes acute lymphoblastic leukemia (ALL)], U266B1 (human myeloma cell line) and the Raji cell line (derived from human lymphoid) utilized as blood cancer models; we also used MCF-7 cells (estrogen receptor-positive breast cancer cells) as a breast cancer cell model; and CHO (ovarian cancer cell line) utilized to study ovarian cancer responses. The cancer cell lines (Pasteur Institute, Tehran, Iran) were grown under the following conditions: the CT-26, MOLT-4, U266B and PC12 in RPMI-1640 (Sigma, St. Louis, MO, USA); the PC3 cells in Ham's F12 (Sigma) and the LNCaP, MCF-7, Raji and CHO cells in DMEM (Sigma) supplied with 10% FBS (Gibco, Grand Island, NY, USA) and penicillin-streptomycin (Sigma) at 37°C in a humidified incubator containing 5% CO₂.

All experiments were performed when the cells reached 85-90% confluence.

Measurement of cell viability by MTT assay. Dilution series (10, 20, 40, 80 and 120 µM) of quercetin were prepared and used for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. All 9 cancer cell lines were seeded at a density of 1.5x10⁴ cells/well and treated with a range of concentrations in triplicate in 96-well cell culture plates, whereupon cell proliferation was assessed using a standard MTT assay. Specifically, the growth inhibitory activity of quercetin was determined using MTT, which correlates the cell number with the mitochondrial reduction of MTT to a blue formazan precipitate. In brief, the cells were plated in 96-well plates and allowed to attach overnight. The medium was then replaced with serum-free medium containing the test compounds and cells were incubated at 37°C for 72 h. The medium was then replaced with fresh medium containing 1 ng/ml MTT. Following incubation at 37°C for 2-4 h, the wells were aspirated, the dye was solubilized in DMSO and the absorbance was measured at 570 nm using a BioTek Instruments EL800 Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA). The viability of cells was compared with that of the control cells.

Detection of necrosis and apoptosis by flow cytometry. For the evaluation of apoptosis using the Annexin V/PI method, the LNCaP, CT-26, MOLT-4 and Raji cells were seeded in 12-well plates (2x10⁵ cells/well). The cells were cultured and incubated (with 5% CO₂ and 95% air) at 37°C. Various concentrations of quercetin (10, 20, 40, 80 and 120 µM were dissolved...
Nadim F. Bechara
Department of Clinical Pharmacology, Faculty of Pharmacy, Lebanese University, Beirut, Lebanon

A lay summary is not available for this document.
At the end of the experiment (36 days following treatment), all surviving animals were sacrificed, and tumors from all animals were dissected and the poly-D-lysine-coated coverslips for TUNEL assay were positioned. An increase in the percentage of apoptotic cells in the treated as compared to the control groups was observed; however, it did not reach statistical significance (P>0.05; Fig. 5).

**Discussion**

In spite of many advances in cancer therapy, cancer is still one of the major causes of mortality worldwide. Natural products, particularly flavones found in the human diet, have been found to exert anti-proliferative and apoptosis-promoting effects against cancer cells (60,61). The current study demonstrated...
that quercetin induces the apoptosis of various cancer cell lines. Furthermore, a significant increase in the survival rate and a significant reduction in tumor volume was observed in tumor-bearing animals treated with quercetin.

Previous studies have shown that grape stem extracts have an ability to inhibit the growth of colon (HT29), breast (MCF-7), renal (Caki-1) and thyroid (K1) cancer cell lines (62,63). These extracts are rich in flavonols, particularly quercetin and rutin (63). Importantly, quercetin was found to be in both aglycon and glycoside forms (64). The inhibitory effect of quercetin on cancer cell growth is attributed to the inhibition of survival signaling proteins, such as protein kinase C (PKC-\(\alpha\)) and the activation of death signals, such as PKC-\(\delta\) (63). Moreover, grape stem extracts seem to present an anti-angiogenic potential evident by VEGF downregulation (65).

Furthermore, quercetin induces pro-apoptotic effects via different mechanisms involving antioxidant effects and the suppression of p53 gene and BCL-2 protein (66). The suppression of BCL-2 gene transcription diminishes the inhibitory effects on BAD protein in the mitochondria, which is considered as the initiator of apoptosis for the intrinsic pathway (67).

The role of quercetin in apoptosis mediated by p53 has been studied in many cancer cell lines. When p53 is inhibited, cells become more susceptible toward cytotoxicity induced by quercetin (68). Apart from cell cycle regulation and the induction of apoptosis, p53 acts as a modulator of intracellular levels of ROS. In this regard, p53 exerts antioxidant effects in cells with no or low stress through the regulation of genes involved in such activity, which comprises microsomal GSH

| Cell line | 24 h   | 48 h   | 72 h   |
|-----------|--------|--------|--------|
| CT-26     | 118.1±5.55 | 97.5±4.31 | 27.2±1.52 |
| LNCaP     | 110.7±4.30 | 72.6±5.15 | 21.7±2.31 |
| PC3       | >120   | 81.9±3.27 | 36±1.98  |
| PC12      | 99.3±6.11 | 65.2±4   | 11.8±2.27 |
| MCF-7     | 105.4±5.2 | 52.5±3.28 | 13.7±2.61 |
| MOLT-4    | 64.9±3.5 | 28.6±2.23 | 2.91±0.54 |
| U266B1    | 54.3±4.5 | 25±1.96  | 6.13±0.73 |
| Raji      | 66.5±3.57 | 19.2±2.83 | 3.52±0.46 |
| CHO       | >120   | 70.7±3.44 | 23.4±3.11 |

IC\(_{50}\) values were calculated as previously described by Entezari Heravi et al (59).
HASHEMZAEI et al: APOPTOSIS-INDUCING EFFECTS OF QUERCETIN

transferase homolog PIG12 (69), aldehyde dehydrogenase 4 family member A1 (ALDH4A1) (70), Gpx1, manganese superoxide dismutase (SOD2) (71) and catalase (72). Some studies, however, have suggested that the effect of quercetin may be independent of p53. Although apoptotic cell death caused by DNA damage is often mediated by p53, there are other proteins, such as p63 and p73, which may be involved in this mechanism (73). Chien et al demonstrated that quercetin-induced apoptotic cell death was accompanied by a decrease in p53 expression in breast cancer cells (74). Additionally, quercetin inhibited the metabolic activity and induced cell death by apoptosis, followed by an increase in BAX expression with a concomitant decrease in the expression of anti-apoptotic proteins.

Quercetin has also been found to modulate the PI3K/Akt/mTOR pathway (75). The flavonoid has structural homology to the PI3K inhibitor, LY294002 (LY) and as expected, the phytochemical was found to inhibit the PI3K-Akt pathway in a similar manner to the inhibition elicited by LY in the breast cancer cell lines, HCC1937 and T47D (76). Breast cancer invasion was found to be suppressed by quercetin through the inactivation of the PKC/ERK/AP-1-dependent MMP-9 activation (76).

Quercetin exerts anticancer effects through the cell death domain mechanism at the cell surface (67). Quercetin activated the cell death domain which leads to FAS and FADD activation, and the induction of cell death in a cancer cell line via activation of caspase 8 (67). The above-mentioned findings are in accordance with the findings of the present study, which

Figure 3. (A) In vivo tumor growth inhibition in BALB/c mice treated with various doses of quercetin (50, 100 and 200 mg/kg; intraperitoneally) induced CT26 and (B) MCF-7 cell line. There were significant differences after 18 days of treatment between the quercetin-treated groups and the control group (dextrose 5%). P<0.001.

Figure 4. In vivo therapeutic efficacy of quercetin in BALB/c mice bearing (A) CT26 and (B) MCF-7 tumors following the intraperitoneal injection of quercetin at multiple doses (50, 100 and 200 mg/kg).

Figure 5. Percentage apoptosis in tumor slices from mice bearing CT-26 and MCF-7 tumors treatment with various concentration of quercetin (50, 100 and 200 mg/kg; intraperitoneally) as assessed by TUNEL assay.
demonstrated the apoptotic-inducing properties of quercetin as assessed by the Annexin V/PI method.

The expression of heat shock proteins (HSPs) in almost all forms of cancer is elevated (58). Badzioł et al showed that quercetin decreased the transcription and translation of HSP27 and 72 in the T98G cell line (58). HSPs are involved in cell proliferation and the inhibition of their production leads to cell apoptosis (77). This is well in accordance with our study, as we demonstrated that apoptosis was induced in quercetin-treated cancer cell lines. HSP27 has been reported to promote the development of leukemia by protecting tumor cells from apoptosis through various mechanisms. Another study investigated the effects of small hairpin (sh)RNA-mediated HSP27 knockdown on the anticancer effects of quercetin in U937 human leukemia cells. The results indicated that shHSP27 and quercetin synergistically inhibited U937 cell proliferation and induced apoptosis by reducing the Bcl2/Bax ratio. Moreover, this combined treatment significantly suppressed the infiltration of tumor cells and the expression of the angiogenesis-associated proteins, hypoxia-inducible factor 1α (HIF1α) and vascular endothelial growth factor (VEGF). In comparison with shHSP27 or quercetin separately, shHSP27 and quercetin together, notably decreased the expression of cyclin D1, and thus the cell cycle was arrested at the G1 phase (78). Furthermore, the Notch/AKT/mTOR signaling pathway contributes to tumor aggressiveness; quercetin plus shHSP27 has been shown to significantly decrease Notch 1 expression and the phosphorylation levels of the downstream signaling proteins, mTOR and AKT (79).

The anticancer effects of quercetin have been confirmed in many studies (36,42,44). Specifically, in vitro and in vivo studies have suggested that quercetin possesses anticancer activity against different tumors; e.g. colon, lung, breast and prostate cancer (78,80-84). Quercetin can exert its anticancer effects through different mechanisms, including the inhibition of DNA topoisomerase I/II, the release of cytochrome c, the activation of caspase 3, and HSP27 and 72 elevation (37,58,85).

An in vivo examination of the effects of quercetin in mice bearing CT-26 tumors was performed for the first time in this study, at least to the best of our knowledge. The results revealed that quercetin significantly reduced the tumor volume and increased animal survival. Previous studies have provided evidence for the anticancer effects of quercetin on breast and prostate cancers in vivo (86,87), an observation which was verified in the current study using the MCF-7 breast cancer in vivo model.

Importantly, quercetin can exert tumor suppressive effects by interfering with the cell cycle. The molecular targets of this flavonoid include p27, topoisomerase II, p21 and cyclin B (88,89). Depending on the tumor origin, quercetin is able to block the cell cycle at G2/M or at the G1/S transition (90,91). In breast cancer cell lines, a low dose of quercetin has been shown to induce mild DNA damage and Chk2 activation, which is the main regulator of p21 expression (92). In addition, quercetin has been shown to downregulate cyclin B1 and CDK1, essential components of G2/M cell cycle progression (92). Moreover, quercetin can inhibit the recruitment of NF-Y, a key transcription factor, which binds to the cyclin B1 gene promoter and leads to transcriptional cessation. In the human hepatoma cell line (HepG2), quercetin upregulated p21, p27 and p53, and consequently the cells were arrested at the G1 phase (93).

Furthermore, quercetin has been shown to inhibit NF-kB-evoked pathways of cell survival and reduce pro-inflammatory cytokine expression that finally leads to cancer formation (94). Notably, quercetin inhibits the production of tumor necrosis factor (TNF)-α, a major pro-inflammatory molecule involved in chronic inflammatory diseases, which may develop into tumors. The quercetin-induced suppression of TNF-α results in the stimulation of anti-inflammatory cytokines through the inhibition of NF-kB activation (95). TNF-α is a major regulator of the cellular release of other chemokines, cytokines and other inflammatory mediators, and thus can be considered as a potential target for the treatment of inflammatory diseases and inflammation-driven cancer. In the current study, quercetin was able to suppress tumor growth and improve animal survival (independent of its action on the induction of apoptosis).

Quercetin seems to play an inhibitory role in angiogenesis in human prostate tumor growth. A recent study using an animal model, indicated that low doses of quercetin inhibited the following angiogenic stages: proliferation and migration, as well as the invasion and tube formation of endothelial cells. Protein expression analysis of prostate cancer cells treated with quercetin revealed the inhibition of the VEGF-induced phosphorylation of VEGFR-2 and its downstream targets, such as mTOR, Akt, and ribosomal S6 kinase (86). Thus, quercetin can decrease tumor volume and increase animal survival rate following systemic administration, a finding which is consistent with the results of the present study.

The oral administration of quercetin is recommended for cancer prevention. It has been shown that a diet supplemented with 2% quercetin significantly reduced the onset of colorectal cancer (96). In addition, in vitro studies have proved its potency in inhibiting the proliferation of colon cancer cells of different lineages (97,98). However, in a phase-1 clinical study performed at the University of Birmingham for the evaluation of the non-toxic and anticancer efficacy of quercetin in terminally ill cancer patients, no patient achieved conventional radiological response according to the WHO criteria, despite favorable indications of its anticancer activity (99).

In conclusion, our results demonstrate that quercetin inhibits the growth of a panel of 9 cancer cell lines with various IC_{50} values. Cell growth inhibition was attributed to the induction of apoptosis, evident in the CT-26, PC-12, LNCaP and PC-3 cancer cell lines. Furthermore, our results demonstrated that quercetin reduced CT-26 and MCF-7 tumor volume in a mouse model and increased animal survival; however, we did not verify increased in situ apoptosis in the induced tumors. The current study results strongly suggest that quercetin has potential for therapeutic application in neoplasia; however, further studies are required to confirm these findings.

Acknowledgements

Special thanks to Zabol University of Medical Sciences for their financial support.

References

1. Schnekenburger M, Dicato M and Diederich M: Plant-derived epigenetic modulators for cancer treatment and prevention. Biotechnol Adv 32: 1123-1132, 2014.
48. Gao X, Wang B, Wei X, Men K, Zheng F, Zhou Y, Zheng Y, Gou M, Huang M, Guo G, *et al.*: Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. J Oncol 2012: 703072, 2012.

49. Cao HH, Tse AK, Kwan HY, Yu H, Cheng CY, Su T, Fong WF, and Yu ZL: Quercetin exerts anti-melanoma activities and inhibits STAT3: signaling. Biochem Pharmacol 87: 424-434, 2014.

50. Spagnuolo C, Russo M, Bilotta S, Tedesco I, Laratta B and Russo GL: Dietary polyphenols in cancer prevention: the example of the antioxidant activity of quercetin in leukemia. Ann N Y Acad Sci 1259: 95-103, 2012.

51. Araújo JR, Gonçalves P and Martel F: Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr Res 31: 77-87, 2011.

52. Entezari Heravi R, Hadizadeh F, Sankian M, Tavakol Afshari J, et al: Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 15: 190, 2014.

53. Westerink RHS and Ewing AG: The PC12 cell as model for the study of p53 and apoptosis. Cell Death Differ 17: 335-344, 2010.

54. Appearlu A, Stagos D, Galitziou E, Spyrou A, Haroutounian S, Apostolou A, Stagos D, Apostolou A, et al: Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line. Eur J Pharm Sci 44: 479-86, 2011.

55. Tag L, Gabrielson NP, Uckun FM, Fan TM and Cheng J: Size-dependent tumor penetration and in vivo efficacy of mono-disperse drug-silica nanoconjugates. Mol Pharm 10: 883-92, 2013.

56. Bądziuk D, Jakubowicz-Gil J, Langner E, Rzeski W, Głowniak K, et al: Novel selective Cox-2 inhibitors induce apoptosis. Adv Med Sci. 58: 397-404, 2013.

57. Boudioudi D, Keramati S, Esfand B, Shokri M, et al: Anticarcinogenic activity of polyphenolic extracts from grape stems against breast, colon, renal and thyroid cancer cells. Toxicol Lett 230: 218-224, 2014.

58. Erlund I, Kosonen T, Alftan G, Määnpää J, Perttunen K, et al: Pharmacokinetics and antioxidant function for the tumor-suppressor gene p53 in the retinal ganglion cell. Invest Opthalmol Vis Sci 49: 4237-4244, 2008.

59. O'Connor JC, Wallace DM, O'Brien CJ and Cotter TG: A novel antioxidant function for the tumor-suppressor gene p53 in the retinal ganglion cell. Invest Opthalmol Vis Sci 49: 4237-4244, 2008.

60. Chahar MK, Sharma N, Dobhal MP and Joshi YC: Flavonoids: A versatile source of anticancer drugs. Pharmacogn Rev 5: 1-12, 2011.

61. Russo GL: Dietary polyphenols in cancer prevention: the anticancer activity of polyphenolic extracts from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56: 545-553, 2000.

62. Stagos D, Apostolou A, Poulos E, Kermeniotou E, Mpatzilioti A, et al: Anticarcinogenic potential of grape stem extract through inhibition of VEGFR-2 regulated AKT/mTOR/P70S6K signaling in human breast cancer MDA-MB-231 cells. Hum Exp Toxicol 28: 493-503, 2009.

63. Seo HS, Ku MJ, Choi HS, Park SY: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling in human breast cancer cells. Carcinogenesis 29: 1807-1815, 2008.

64. Lee C-H, Hong H-M, Chang Y-Y and Chang W-I: W-inhibitory effect of heat shock protein (Hsp) 27 potenitates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells. Biochimie 94: 1382-1389, 2012.

65. Catanarzo D, Ragazzi E, Vianello C, Caparrotta L and Montopoli M: Effect of quercetin on cell cycle and cyclin expression in ovarian carcinoma and osteosarcoma cell lines. Nat Prod Commun 10: 328-329, 2015.

66. Chen X, Dong XS, Gao HY, Jiang YF, Jin YL, Chang YY, Chen LY and Wang JH: Suppression of Hsp27 increases the anti tumor effects of quercetin in human leukemia U937 cells. Mol Med Rep 13: 689-696, 2016.

67. Neuhouser ML: Dietary flavonoids and cancer risk: Evidence from human population studies. Nutr Cancer 50: 1-7, 2004.

68. Li W, Liu M, Xu YF, Feng Y, Che JP, Wang GC, and Zheng JH: Combination of quercetin and hyperoside inhibits anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a. Oncol Rep 31: 117-124, 2014.

69. Ltd JH, Je SK, Kim J and Park SY: Quercetin-induced autophagy flux enhances TRAIL-mediated tumor cell death. Oncol Rep 34: 375-381, 2015.

70. Stagos D, Apostolou A, Haroutounian SA, Tsatsakis AM, Trakadas GN, Hayes AW and Kouretas D: Anticarcinogenic activity of polyphenolic extracts from grape stems against breast, colon, renal and thyroid cancer cells. Toxicol Lett 230: 218-224, 2014.

71. Pratheeekumar P, Budhrajaa A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One 7: e47516, 2012.

72. Stagos D, Apostolou A, Poullios E, Keramiotou E, Mpatzillioti A, et al: Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line. Eur J Pharm Sci 44: 479-86, 2011.

73. Chahar MK, Sharma N, Dobhal MP and Joshi YC: Flavonoids: A versatile source of anticancer drugs. Pharmacogn Rev 5: 1-12, 2011.

74. Catanzaro D, Ragazzi E, Vianello C, Caparrotta L and Montopoli M: Effect of quercetin on cell cycle and cyclin expression in ovarian carcinoma and osteosarcoma cell lines. Nat Prod Commun 10: 328-329, 2015.

75. Chen X, Dong XS, Gao HY, Jiang YF, Jin YL, Chang YY, Chen LY and Wang JH: Suppression of Hsp27 increases the anti tumor effects of quercetin in human leukemia U937 cells. Mol Med Rep 13: 689-696, 2016.

76. Neuhouser ML: Dietary flavonoids and cancer risk: Evidence from human population studies. Nutr Cancer 50: 1-7, 2004.

77. Li W, Liu M, Xu YF, Feng Y, Che JP, Wang GC, and Zheng JH: Combination of quercetin and hyperoside inhibits anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a. Oncol Rep 31: 117-124, 2014.

78. Ltd JH, Je SK, Kim J and Park SY: Quercetin-induced autophagy flux enhances TRAIL-mediated tumor cell death. Oncol Rep 34: 375-381, 2015.

79. Stagos D, Apostolou A, Haroutounian SA, Tsatsakis AM, Trakadas GN, Hayes AW and Kouretas D: Anticarcinogenic activity of polyphenolic extracts from grape stems against breast, colon, renal and thyroid cancer cells. Toxicol Lett 230: 218-224, 2014.

80. Pratheeekumar P, Budhrajaa A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One 7: e47516, 2012.

81. Stagos D, Apostolou A, Poullios E, Keramiotou E, Mpatzillioti A, et al: Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line. Eur J Pharm Sci 44: 479-86, 2011.

82. Chang MK, Sharma N, Dobhal MP and Joshi YC: Flavonoids: A versatile source of anticancer drugs. Pharmacogn Rev 5: 1-12, 2011.

83. Pratheeekumar P, Budhrajaa A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One 7: e47516, 2012.

84. Stagos D, Apostolou A, Poullios E, Keramiotou E, Mpatzillioti A, et al: Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line. Eur J Pharm Sci 44: 479-86, 2011.

85. Chahar MK, Sharma N, Dobhal MP and Joshi YC: Flavonoids: A versatile source of anticancer drugs. Pharmacogn Rev 5: 1-12, 2011.
90. Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, Bertoncelli L, Cooper EL and Cossarizza A: Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med 2011: 591356, 2011.

91. Zhou J, Fang L, Yao WX, Zhao X, Wei Y, Zhou H, Xie H, Wang LY and Chen LJ: Effect of quercetin on heat shock protein expression in HepG2 cells determined by SILAC. Zhonghua Zhong Liu Za Zhi 33: 737-741, 2011 (In Chinese).

92. Jeong JH, An JY, Kwon YT, Rhee JG and Lee YJ: Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression. J Cell Biochem 106: 73-82, 2009.

93. Mu C, Jia P, Yan Z, Liu X, Li X and Liu H: Quercetin induces cell cycle G1 arrest through elevating Cdk inhibitors p21 and p27 in human hepatoma cell line (HepG2). Methods Find Exp Clin Pharmacol 29: 179-183, 2007.

94. Crespo I, García-Mediavilla MV, Gutiérrez B, Sánchez-Campos S, Tuñón MJ and González-Gallego J: A comparison of the effects of kaempferol and quercetin on cytokine-induced pro-inflammatory status of cultured human endothelial cells. Br J Nutr 100: 968-976, 2008.

95. Nair MP, Mahajan S, Reynolds JL, Aalinkeel R, Nair H, Schwartz SA and Kandaswami C: The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-kappa beta system. Clin Vaccine Immunol 13: 319-328, 2006.

96. Matsukawa Y, Nishino H, Okuyama Y, Matsui T, Matsumoto T, Matsumura S, Shimizu Y, Sowa Y and Sakai T: Effects of quercetin and/or restraint stress on formation of aberrant crypt foci induced by azoxymethane in rat colons. Oncology 54: 118-121, 1997.

97. Shan BE, Wang MX and Li RQ: Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest 27: 604-612, 2009.

98. Yang K, Lamprecht SA, Liu Y, Shinozaki H, Fan K, Leung D, Newmark H, Steele VE, Kelloff GJ and Lipkin M: Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon. Carcinogenesis 21: 1655-1660, 2000.

99. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J and Kerr DJ: Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668, 1996.